News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Trump set an 8 p.m. ET deadline for Iran to lift its blockade of the Strait of Hormuz.
  • Global markets paused and equities finished largely flat amid heightened geopolitical uncertainty.
  • Data and forecasts signaled rising price pressures, increasing market unease.
  • Super Micro launched an independent probe after U.S. DOJ-linked indictments over alleged server exports to China.
  • Artemis II traversed the lunar far side, serving as a key test ahead of crewed moon landings.
  • Colombian and Mexican equities fell, COLCAP down 1.06% and S&P/BMV IPC down 0.66%.
  • Moscow's MOEX rose 0.48%, led by Oil & Gas, Power and Manufacturing gains.

Latest Articles

Tariffs Keep Pressuring Margins as Companies Prepare for Earnings Season

Tariffs Keep Pressuring Margins as Companies Prepare for Earnings Season

U.S. companies continue to describe tariffs as manageable, but comments during early earnings season suggest profit margins remain under pressure as some costs are passed to consumers. Retailers and manufacturers, from Amazon and Procter & Gamble to Fastenal and Tractor Supply, have reported rising prices in certain categories and cautious consumer…

RBC Keeps Neutral Rating on Sarepta as Elevidys Growth Faces Headwinds

RBC Keeps Neutral Rating on Sarepta as Elevidys Growth Faces Headwinds

RBC Capital reiterated a Sector Perform rating and $18 price target on Sarepta Therapeutics (SRPT), pointing to decelerating uptake of the company's gene therapy ELEVIDYS and a cash position strained by ongoing negative free cash flow. Analysts differ on near-term sales expectations for ELEVIDYS and the broader commercial outlook, while preliminary…

Drugmakers Lean on AI to Accelerate Trials and Regulatory Workflows

Drugmakers Lean on AI to Accelerate Trials and Regulatory Workflows

Leading pharmaceutical and smaller biotech companies described how artificial intelligence is already shortening labor-intensive drug development tasks such as finding trial participants and preparing regulatory documents. While the technology has yet to produce the next transformative therapeutic molecule, attendees at a major industry conference …

Barrick’s North America IPO Plan Dependent on Newmont’s Consent, Internal Papers and Executives Say

Barrick’s North America IPO Plan Dependent on Newmont’s Consent, Internal Papers and Executives Say

Barrick Gold’s plan to separate its North American assets into a standalone listing is contingent on approvals and capital commitments from joint venture partner Newmont, according to company documents and former Barrick executives. Newmont holds pre-emptive rights and consent provisions over transfers of the Nevada Gold Mines interest, and Barrick…

Exxon’s XTO Markets Select Eagle Ford Holdings as Part of Portfolio Review

Exxon’s XTO Markets Select Eagle Ford Holdings as Part of Portfolio Review

Exxon Mobil’s natural gas subsidiary XTO Energy has opened a virtual data room to solicit buyers for select Eagle Ford assets in South Texas. The package spans roughly 168,000 net acres, includes over a thousand wells and is valued at more than $1 billion. Exxon is handling the marketing internally and says the move is part of an ongoing portfolio …

Raymond James Lifts Travelers Price Target to $330 on Stronger EPS Outlook

Raymond James Lifts Travelers Price Target to $330 on Stronger EPS Outlook

Raymond James raised its price objective on Travelers (TRV) to $330 from $310 and kept a Strong Buy rating after increasing operating EPS projections for 2026 and 2027. The firm attributes the improved outlook to higher expected net investment income, more aggressive share repurchases and more favorable prior-year reserve development assumptions, w…

William Blair Starts Coverage of Xylem With Outperform Call

William Blair Starts Coverage of Xylem With Outperform Call

William Blair initiated coverage of Xylem Inc. (NYSE: XYL) with an Outperform rating, highlighting the company’s position as a leading pure-play water technology provider. The research note emphasized Xylem’s broad portfolio across the water cycle, its sizeable installed base supported by thousands of service professionals, and mission-critical sol…

Raymond James Lifts Independent Bank Target to $94 After Strong Q4 Results

Raymond James Lifts Independent Bank Target to $94 After Strong Q4 Results

Raymond James increased its price target on Independent Bank Corp (INDB) to $94 from $84 and reiterated a Strong Buy rating following the bank's better-than-expected fourth-quarter 2025 results. The firm cited expanding core net interest margins driven by asset repricing and lower funding costs, plus loan growth, buybacks, and tight expense control…